Literature DB >> 12000224

Cross-linked polyhemoglobin-superoxide dismutase-catalase supplies oxygen without causing blood-brain barrier disruption or brain edema in a rat model of transient global brain ischemia-reperfusion.

D Douglas Powanda1, Thomas M S Chang.   

Abstract

In strokes, myocardial infarctions, severe sustained hemorrhagic shock, and donor organs, inadequate blood supply results in lack of oxygen to the tissue (ischemia). If ischemia is sustained, reperfusion with the needed oxygen can result in tissue injury (ischemia-reperfusion injury) due to formation of reactive oxygen species. We are studying an oxygen-carrying solution with anitoxidant activity formed by cross-linking hemoglobin, superoxide dismutase, and catalase to form PolyHb-SOD-CAT. The present report studies its effect on the blood-brain barrier and cerebral edema when used in a transient global brain ischemia-reperfusion rat model. We compare this solution to sham-control, oxygenated saline, stroma-free hemoglobin (SF-Hb), polymerized hemoglobin (PolyHb), and a mixture of SF-Hb, SOD, and CAT in free solution. The results show that the cross-linked PolyHb-SOD-CAT solution, unlike the other solutions, can supply oxygen to ischemic tissues without causing reperfusion injury in the transient global brain ischemia-reperfusion model.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12000224     DOI: 10.1081/bio-120002725

Source DB:  PubMed          Journal:  Artif Cells Blood Substit Immobil Biotechnol        ISSN: 1073-1199


  14 in total

1.  Synthesis and characterization of hemoglobin conjugates with antioxidant enzymes via poly(ethylene glycol) cross-linker (Hb-SOD-CAT) for protection from free radical stress.

Authors:  Venkatareddy Nadithe; You Han Bae
Journal:  Int J Biol Macromol       Date:  2010-08-17       Impact factor: 6.953

Review 2.  Nanobiotechnology for hemoglobin-based blood substitutes.

Authors:  T M S Chang
Journal:  Crit Care Clin       Date:  2009-04       Impact factor: 3.598

3.  Nanobiotechnological modification of hemoglobin and enzymes from this laboratory.

Authors:  Thomas Ming Swi Chang
Journal:  Biochim Biophys Acta       Date:  2008-06-17

4.  The immunological properties of stroma-free polyhemolysate containing catalase and superoxide dismutase activities prepared by polymerized bovine stroma-free hemolysate.

Authors:  Hongli Zhu; Qianqian Du; Chao Chen; Thomas Ming Swi Chang
Journal:  Artif Cells Blood Substit Immobil Biotechnol       Date:  2010-04

5.  Modulation of oxidative stability of haemoglobin inside liposome-encapsulated haemoglobin.

Authors:  Vibhudutta Awasthi; Vivek R Yadav; Beth Goins; William T Phillips
Journal:  J Microencapsul       Date:  2012-12-11       Impact factor: 3.142

Review 6.  Bio-inspired nanomedicine strategies for artificial blood components.

Authors:  Anirban Sen Gupta
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2017-03-15

Review 7.  Blood replacement with nanobiotechnologically engineered hemoglobin and hemoglobin nanocapsules.

Authors:  Thomas Ming Swi Chang
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2010 Jul-Aug

8.  Oxygen-binding heme complexes of peptides designed to mimic the heme environment of myoglobin and hemoglobin.

Authors:  M Zouhair Atassi; Catherine Childress
Journal:  Protein J       Date:  2005-01       Impact factor: 2.371

9.  Novel Nanodimension artificial red blood cells that act as O2 and CO2 carrier with enhanced antioxidant activity: PLA-PEG nanoencapsulated PolySFHb-superoxide dismutase-catalase-carbonic anhydrase.

Authors:  Wei Gao; Yuzhu Bian; Thomas M S Chang
Journal:  Artif Cells Nanomed Biotechnol       Date:  2013-01-22       Impact factor: 5.678

10.  Lowering of elevated tissue PCO2 in a hemorrhagic shock rat model after reinfusion of a novel nanobiotechnological polyhemoglobin-superoxide dismutase-catalase-carbonic anhydrase that is an oxygen and a carbon dioxide carrier with enhanced antioxidant properties.

Authors:  Yuzhu Bian; Gao Wei; Thomas M S Chang
Journal:  Artif Cells Nanomed Biotechnol       Date:  2013-02       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.